IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-45306-y.html
   My bibliography  Save this article

Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma

Author

Listed:
  • Shaoshuai Tang

    (Fudan University)

  • Yunzhi Wang

    (Fudan University)

  • Rongkui Luo

    (Fudan University)

  • Rundong Fang

    (Fudan University)

  • Yufeng Liu

    (Fudan University)

  • Hang Xiang

    (Fudan University)

  • Peng Ran

    (Fudan University)

  • Yexin Tong

    (Fudan University)

  • Mingjun Sun

    (Fudan University)

  • Subei Tan

    (Fudan University)

  • Wen Huang

    (Fudan University)

  • Jie Huang

    (Fudan University)

  • Jiacheng Lv

    (Fudan University)

  • Ning Xu

    (Fudan University)

  • Zhenmei Yao

    (Fudan University)

  • Qiao Zhang

    (Fudan University)

  • Ziyan Xu

    (Fudan University)

  • Xuetong Yue

    (Fudan University)

  • Zixiang Yu

    (Fudan University)

  • Sujie Akesu

    (Fudan University)

  • Yuqin Ding

    (Fudan University
    Shanghai Institute of Medical Imaging)

  • Chen Xu

    (Fudan University)

  • Weiqi Lu

    (Fudan University)

  • Yuhong Zhou

    (Fudan University)

  • Yingyong Hou

    (Fudan University)

  • Chen Ding

    (Fudan University)

Abstract

Soft tissue sarcoma is a broad family of mesenchymal malignancies exhibiting remarkable histological diversity. We portray the proteomic landscape of 272 soft tissue sarcomas representing 12 major subtypes. Hierarchical classification finds the similarity of proteomic features between angiosarcoma and epithelial sarcoma, and elevated expression of SHC1 in AS and ES is correlated with poor prognosis. Moreover, proteomic clustering classifies patients of soft tissue sarcoma into 3 proteomic clusters with diverse driven pathways and clinical outcomes. In the proteomic cluster featured with the high cell proliferation rate, APEX1 and NPM1 are found to promote cell proliferation and drive the progression of cancer cells. The classification based on immune signatures defines three immune subtypes with distinctive tumor microenvironments. Further analysis illustrates the potential association between immune evasion markers (PD-L1 and CD80) and tumor metastasis in soft tissue sarcoma. Overall, this analysis uncovers sarcoma-type-specific changes in proteins, providing insights about relationships of soft tissue sarcoma.

Suggested Citation

  • Shaoshuai Tang & Yunzhi Wang & Rongkui Luo & Rundong Fang & Yufeng Liu & Hang Xiang & Peng Ran & Yexin Tong & Mingjun Sun & Subei Tan & Wen Huang & Jie Huang & Jiacheng Lv & Ning Xu & Zhenmei Yao & Qi, 2024. "Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma," Nature Communications, Nature, vol. 15(1), pages 1-24, December.
  • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45306-y
    DOI: 10.1038/s41467-024-45306-y
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-45306-y
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-024-45306-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Jessica Burns & Christopher P. Wilding & Lukas Krasny & Xixuan Zhu & Madhumeeta Chadha & Yuen Bun Tam & Hari PS & Aswanth H. Mahalingam & Alexander T. J. Lee & Amani Arthur & Nafia Guljar & Emma Perki, 2023. "The proteomic landscape of soft tissue sarcomas," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    2. Ryuhjin Ahn & Valérie Sabourin & Alicia M. Bolt & Steven Hébert & Stephanie Totten & Nicolas De Jay & Maria Carolina Festa & Yoon Kow Young & Young Kyuen Im & Tony Pawson & Antonis E. Koromilas & Will, 2017. "The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression," Nature Communications, Nature, vol. 8(1), pages 1-14, April.
    3. Ge Qin & Xin Wang & Shubiao Ye & Yizhuo Li & Miao Chen & Shusen Wang & Tao Qin & Changlin Zhang & Yixin Li & Qian Long & Huabin Hu & Dingbo Shi & Jiaping Li & Kai Zhang & Qinglian Zhai & Yanlai Tang &, 2020. "NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer," Nature Communications, Nature, vol. 11(1), pages 1-16, December.
    4. Kosuke Yoshihara & Maria Shahmoradgoli & Emmanuel Martínez & Rahulsimham Vegesna & Hoon Kim & Wandaliz Torres-Garcia & Victor Treviño & Hui Shen & Peter W. Laird & Douglas A. Levine & Scott L. Carter , 2013. "Inferring tumour purity and stromal and immune cell admixture from expression data," Nature Communications, Nature, vol. 4(1), pages 1-11, December.
    5. Makoto Hirata & Naofumi Asano & Kotoe Katayama & Akihiko Yoshida & Yusuke Tsuda & Masaya Sekimizu & Sachiyo Mitani & Eisuke Kobayashi & Motokiyo Komiyama & Hiroyuki Fujimoto & Takahiro Goto & Yukihide, 2019. "Integrated exome and RNA sequencing of dedifferentiated liposarcoma," Nature Communications, Nature, vol. 10(1), pages 1-12, December.
    6. Yong Zheng & Cunjie Zhang & David R. Croucher & Mohamed A. Soliman & Nicole St-Denis & Adrian Pasculescu & Lorne Taylor & Stephen A. Tate & W. Rod Hardy & Karen Colwill & Anna Yue Dai & Rick Bagshaw &, 2013. "Temporal regulation of EGF signalling networks by the scaffold protein Shc1," Nature, Nature, vol. 499(7457), pages 166-171, July.
    7. Florent Petitprez & Aurélien Reyniès & Emily Z. Keung & Tom Wei-Wu Chen & Cheng-Ming Sun & Julien Calderaro & Yung-Ming Jeng & Li-Ping Hsiao & Laetitia Lacroix & Antoine Bougoüin & Marco Moreira & Gui, 2020. "B cells are associated with survival and immunotherapy response in sarcoma," Nature, Nature, vol. 577(7791), pages 556-560, January.
    8. Wengui Shi & Gengyuan Zhang & Zhijian Ma & Lianshun Li & Miaomiao Liu & Long Qin & Zeyuan Yu & Lei Zhao & Yang Liu & Xue Zhang & Junjie Qin & Huili Ye & Xiangyan Jiang & Huinian Zhou & Hui Sun & Zuoyi, 2021. "Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer," Nature Communications, Nature, vol. 12(1), pages 1-19, December.
    9. Daniel S. Chen & Ira Mellman, 2017. "Elements of cancer immunity and the cancer–immune set point," Nature, Nature, vol. 541(7637), pages 321-330, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Nadège Gruel & Chloé Quignot & Laëtitia Lesage & Sophie El Zein & Sylvie Bonvalot & Dimitri Tzanis & Khadija Ait Rais & Fabien Quinquis & Bastien Manciot & Julien Vibert & Nadine El Tannir & Ahmed Dah, 2024. "Cellular origin and clonal evolution of human dedifferentiated liposarcoma," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    2. Lenka Kasikova & Jana Rakova & Michal Hensler & Tereza Lanickova & Jana Tomankova & Josef Pasulka & Jana Drozenova & Katerina Mojzisova & Anna Fialova & Sarka Vosahlikova & Jan Laco & Ales Ryska & Pav, 2024. "Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    3. Zhongqi Fan & Xinchen Zou & Guangyi Wang & Yahui Liu & Yanfang Jiang & Haoyan Wang & Ping Zhang & Feng Wei & Xiaohong Du & Meng Wang & Xiaodong Sun & Bai Ji & Xintong Hu & Liguo Chen & Peiwen Zhou & D, 2024. "A transcriptome based molecular classification scheme for cholangiocarcinoma and subtype-derived prognostic biomarker," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    4. Maria Pouyiourou & Bianca N. Kraft & Timothy Wohlfromm & Michael Stahl & Boris Kubuschok & Harald Löffler & Ulrich T. Hacker & Gerdt Hübner & Lena Weiss & Michael Bitzer & Thomas Ernst & Philipp Schüt, 2023. "Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial," Nature Communications, Nature, vol. 14(1), pages 1-21, December.
    5. Aditi Sahu & Kivanc Kose & Lukas Kraehenbuehl & Candice Byers & Aliya Holland & Teguru Tembo & Anthony Santella & Anabel Alfonso & Madison Li & Miguel Cordova & Melissa Gill & Christi Fox & Salvador G, 2022. "In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
    6. Dongliang Bian & Liangdong Sun & Junjie Hu & Liang Duan & Haoran Xia & Xinsheng Zhu & Fenghuan Sun & Lele Zhang & Huansha Yu & Yicheng Xiong & Zhida Huang & Deping Zhao & Nan Song & Jie Yang & Xiao Ba, 2023. "Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    7. Jia Wei & Xiaofeng Lu & Qin Liu & Yao Fu & Song Liu & Yang Zhao & Jiawei Zhou & Hui Chen & Meng Wang & Lin Li & Ju Yang & Fangcen Liu & Liming Zheng & Haitao Yin & Yang Yang & Chong Zhou & Ping Zeng &, 2023. "Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    8. Alexandra Gyurdieva & Stefan Zajic & Ya-Fang Chang & E. Andres Houseman & Shan Zhong & Jaegil Kim & Michael Nathenson & Thomas Faitg & Mary Woessner & David C. Turner & Aisha N. Hasan & John Glod & Ro, 2022. "Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    9. E. H. Puttock & E. J. Tyler & M. Manni & E. Maniati & C. Butterworth & M. Burger Ramos & E. Peerani & P. Hirani & V. Gauthier & Y. Liu & G. Maniscalco & V. Rajeeve & P. Cutillas & C. Trevisan & M. Poz, 2023. "Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    10. Heng-Jia Liu & Heng Du & Damir Khabibullin & Mahsa Zarei & Kevin Wei & Gordon J. Freeman & David J. Kwiatkowski & Elizabeth P. Henske, 2023. "mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    11. Feng Xie & Xiaoxue Zhou & Peng Su & Heyu Li & Yifei Tu & Jinjin Du & Chen Pan & Xiang Wei & Min Zheng & Ke Jin & Liyan Miao & Chao Wang & Xuli Meng & Hans Dam & Peter Dijke & Long Zhang & Fangfang Zho, 2022. "Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    12. Miles C. Andrews & Junna Oba & Chang-Jiun Wu & Haifeng Zhu & Tatiana Karpinets & Caitlin A. Creasy & Marie-Andrée Forget & Xiaoxing Yu & Xingzhi Song & Xizeng Mao & A. Gordon Robertson & Gabriele Roma, 2022. "Multi-modal molecular programs regulate melanoma cell state," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    13. Nanda Horeweg & Hagma H. Workel & Dominik Loiero & David N. Church & Lisa Vermij & Alicia Léon-Castillo & Ricki T. Krog & Stephanie M. Boer & Remi A. Nout & Melanie E. Powell & Linda R. Mileshkin & He, 2022. "Tertiary lymphoid structures critical for prognosis in endometrial cancer patients," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    14. Mengxue Zhou & Jiaxin Wang & Jiaxing Pan & Hui Wang & Lujia Huang & Bo Hou & Yi Lai & Fengyang Wang & Qingxiang Guan & Feng Wang & Zhiai Xu & Haijun Yu, 2023. "Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    15. Meriem Messaoudene & Stéphanie Ferreira & Nathalie Saint-Lu & Mayra Ponce & Caroline Truntzer & Romain Boidot & Clément Bescop & Thomas Loppinet & Tanguy Corbel & Céline Féger & Karine Bertrand & Arie, 2024. "The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    16. Mattia Rediti & Aranzazu Fernandez-Martinez & David Venet & Françoise Rothé & Katherine A. Hoadley & Joel S. Parker & Baljit Singh & Jordan D. Campbell & Karla V. Ballman & David W. Hillman & Eric P. , 2023. "Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    17. Akshay J. Patel & Zena N. Willsmore & Naeem Khan & Alex Richter & Babu Naidu & Mark T. Drayson & Sophie Papa & Andrew Cope & Sophia N. Karagiannis & Esperanza Perucha & Gary W. Middleton, 2022. "Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    18. Charlotte K. Y. Ng & Eva Dazert & Tuyana Boldanova & Mairene Coto-Llerena & Sandro Nuciforo & Caner Ercan & Aleksei Suslov & Marie-Anne Meier & Thomas Bock & Alexander Schmidt & Sylvia Ketterer & Xuey, 2022. "Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    19. Lucia Taraborrelli & Yasin Şenbabaoğlu & Lifen Wang & Junghyun Lim & Kerrigan Blake & Noelyn Kljavin & Sarah Gierke & Alexis Scherl & James Ziai & Erin McNamara & Mark Owyong & Shilpa Rao & Aslihan Ka, 2023. "Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    20. Olivia Le Saux & Maude Ardin & Justine Berthet & Sarah Barrin & Morgane Bourhis & Justine Cinier & Yasmine Lounici & Isabelle Treilleux & Pierre-Alexandre Just & Guillaume Bataillon & Aude-Marie Savoy, 2024. "Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma," Nature Communications, Nature, vol. 15(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45306-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.